Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial
Recce Pharmaceuticals’ synthetic anti-infective gel successfully treated a range of skin infections in a midstage test, setting the Australian biotech’s sights on a registrational phase 3 trial.
Recce Pharmaceuticals’ synthetic anti-infective gel successfully treated a range of skin infections in a midstage test, setting the Australian biotech’s sights on a registrational phase 3 trial.
